KAYNES TECHNOLOGY Conference call highlights
Guidance: Kaynes guided 60% revenue growth with EBITDA margins expanding 50bp for FY26 to 15.6% (+200bp for next few years) driven by strong growth across all business verticals and client additions.
Financials: Average monthly order inflow stands at INR5.1bn (versus INR4bnearlier). NWC days stand at 87 and are likely to improve significantly in FY26, driven by inventory optimisation and better production planning.Other non-current assets have increased due to acquisition of old customer contracts with deferred payment terms; new contracts have clear payment terms.
Guidance: Kaynes guided 60% revenue growth with EBITDA margins expanding 50bp for FY26 to 15.6% (+200bp for next few years) driven by strong growth across all business verticals and client additions.
Financials: Average monthly order inflow stands at INR5.1bn (versus INR4bnearlier). NWC days stand at 87 and are likely to improve significantly in FY26, driven by inventory optimisation and better production planning.Other non-current assets have increased due to acquisition of old customer contracts with deferred payment terms; new contracts have clear payment terms.
๐ฅ7โก3๐2๐1๐ซก1
Upcoming facilities: Construction of HDI PCB plant in Chennai and OSAT plant in Sanand is on track and is likely to complete construction by Dec-25. Pilot production from these facilities to start by Q4FY26 with factories likely to be operational in FY27. Five customers are in active talks; one has already issued an RFQ. Much of the capacity will be booked before operations begin, as per the company. Kaynes has applied under SPECS 2.0 and expects to receive PLI benefits. Kaynes has completed its Chamarajanagar facility with a couple of exclusive zones for some large customers and set to start working at higher capacity
๐ฅ3โก1๐1๐ซก1
Capex: Total capex for semicon plant and PCB plant is INR34bn (50% from central and 20โ25% from state government subsidy) and INR14bn (40% from central and 25% state government subsidy). The overall capex is to be completed by FY28 with significant capacity utilisation. Capex for the EMS business would only be the maintenance capex.
๐ฅ2โก1๐1๐1
Order book:
Order book as of Mar-25 stands at INR66bn with majority orders from aerospace, industrial and automotive (margin accretive orders). These orders are higher margin than the ones the company is delivering right now and to be executed over 1โ1.5 years.
Order book as of Mar-25 stands at INR66bn with majority orders from aerospace, industrial and automotive (margin accretive orders). These orders are higher margin than the ones the company is delivering right now and to be executed over 1โ1.5 years.
โค2๐ฅ2๐1
August Electronics, Canada: With the recent acquisition of August Electronics in Canada, Kaynes has strengthened its North American footprint, adding
manufacturing capability in Canada and large high margin customers. August Electronics has better EBITDA margins than the consolidated market (one of the premier vendors in Canada) set to grow at 15โ20%. The acquisition provides the company exposure to sectors such as instrumentation, petroleum, medical and IT (high value addition areas).
manufacturing capability in Canada and large high margin customers. August Electronics has better EBITDA margins than the consolidated market (one of the premier vendors in Canada) set to grow at 15โ20%. The acquisition provides the company exposure to sectors such as instrumentation, petroleum, medical and IT (high value addition areas).
๐ฅ3โก1๐ซก1๐ฆ1
Aerospace: Kaynes has been a strategic partner to ISRO for over a decade and aims to deepen this collaboration, especially in emerging space and defence technologies. With the launch of its subsidiary Mechatronics, the company is
building significant capacity to become a premier supplier of satellite
components and possibly small satellite launch systems. It is also exploring national security applications through Sea Stick Venture, backed by experienced ex-government scientists.
building significant capacity to become a premier supplier of satellite
components and possibly small satellite launch systems. It is also exploring national security applications through Sea Stick Venture, backed by experienced ex-government scientists.
๐ฅ4โก2๐1
Company introduction
Founded in 1998, Kaynes Technology (Kaynes) has over 3 decades of experience in providing conceptual design, process engineering, integrated manufacturing and life-cycle support to OEMs. It is a leading integrated and IoT-enabled solutions provider with capabilities across the entire spectrum of ESDM. Currently, it is operating in the low-volume high-value niche in the EMS space. Industrial
electronics, railway electronics, medical electronics, defence electronics, automotive electronics and IT hardware are the key verticals that Kaynes services. It has served 370+ customers in 28+ countries; including marquee MNCs. Kaynes operates 16 advanced manufacturing facilities to undertake high mix and high value products with variable or flexible volumes. It has evolved as an integrated electronics player by moving into OSAT and HDI PCB.
Founded in 1998, Kaynes Technology (Kaynes) has over 3 decades of experience in providing conceptual design, process engineering, integrated manufacturing and life-cycle support to OEMs. It is a leading integrated and IoT-enabled solutions provider with capabilities across the entire spectrum of ESDM. Currently, it is operating in the low-volume high-value niche in the EMS space. Industrial
electronics, railway electronics, medical electronics, defence electronics, automotive electronics and IT hardware are the key verticals that Kaynes services. It has served 370+ customers in 28+ countries; including marquee MNCs. Kaynes operates 16 advanced manufacturing facilities to undertake high mix and high value products with variable or flexible volumes. It has evolved as an integrated electronics player by moving into OSAT and HDI PCB.
โก2๐1๐1๐1๐1
Key Risk
Currently, the domestic EMS sector is turbo-charged largely due to favourable government policies. Any change in government stance on manufacturing-related
policies, particularly adverse changes, shall be the biggest risk to the EMS sector
growth. Kaynes is one of the largest EMS players in India. As the EMS sector grows,
we see a host of EMS players becoming large. If Kaynes is unable to retain its pace of growth and scale, it shall face challenges in the future from competition; this is potential risk.
Currently, the domestic EMS sector is turbo-charged largely due to favourable government policies. Any change in government stance on manufacturing-related
policies, particularly adverse changes, shall be the biggest risk to the EMS sector
growth. Kaynes is one of the largest EMS players in India. As the EMS sector grows,
we see a host of EMS players becoming large. If Kaynes is unable to retain its pace of growth and scale, it shall face challenges in the future from competition; this is potential risk.
โก2๐ฅ2๐1
Global Health Limited company details report
Global Health Limited is one of the largest private multi-specialty tertiary care providers, operating in the Northern and Eastern regions of India. Under the brand โMedantaโ it operates with a network of 5 hospitals in Gurugram, Indore, Ranchi, Lucknow and Patna. Apart from it, it has an upcoming hospital in Noida. GHL offers a comprehensive range of healthcare services across over 30 specialties and super specialties, including heart institute, cancer, neurology, internal medicines, digestives, kidney & urology, orthopedics, liver transplantation and others. As on 31st December 2024, it has a total bed capacity of 3,042 beds with 2,427 beds operational at a group level. The Groupโs flagship hospital at Gurugram is one of the largest hospitals in India with a capacity of ~1,391 beds in a single location. Additionally, to offer a streamlined pathway for patient referrals, it operates 6 multi-specialty clinics with a diverse range of services such as dialysis, day care procedure, surgeries, general consultations and diagnostic services. To further extend care outside hospitals, it offers homecare services, ranging from sample collections to preventive health checkups, pediatric vaccinations and ICU at home; pharmacies (primarily driven by in-house OP pharmacies at its hospitals). The company also launched โMedanta Labsโ in January 2023 with establishing 22 collection centres across the region it operates in.
Global Health Limited is one of the largest private multi-specialty tertiary care providers, operating in the Northern and Eastern regions of India. Under the brand โMedantaโ it operates with a network of 5 hospitals in Gurugram, Indore, Ranchi, Lucknow and Patna. Apart from it, it has an upcoming hospital in Noida. GHL offers a comprehensive range of healthcare services across over 30 specialties and super specialties, including heart institute, cancer, neurology, internal medicines, digestives, kidney & urology, orthopedics, liver transplantation and others. As on 31st December 2024, it has a total bed capacity of 3,042 beds with 2,427 beds operational at a group level. The Groupโs flagship hospital at Gurugram is one of the largest hospitals in India with a capacity of ~1,391 beds in a single location. Additionally, to offer a streamlined pathway for patient referrals, it operates 6 multi-specialty clinics with a diverse range of services such as dialysis, day care procedure, surgeries, general consultations and diagnostic services. To further extend care outside hospitals, it offers homecare services, ranging from sample collections to preventive health checkups, pediatric vaccinations and ICU at home; pharmacies (primarily driven by in-house OP pharmacies at its hospitals). The company also launched โMedanta Labsโ in January 2023 with establishing 22 collection centres across the region it operates in.
โก2๐ฅ2โค1๐1
Medanta has classified its hospitals into Matured and Developing hospitals. Mature hospitals (operational for over 6 years) include hospitals at Gurugram, Indore and Ranchi. While developing hospitals (operational for less than 6 years) comprise of hospitals at Lucknow and Patna. Under the developing hospital, they launched OutPatient department facility at Patna in 2020, while InPatient department was opened in 2021, with operations commencing during FY22. The rationale behind this was to capture a sizeable demand from Northeast India, particularly from Jharkhand and Nepal. In Q1 FY25, revenue share from the mature and developing hospitals stood at ~73% and 27%, respectively. In Q2 FY25, the same stood at ~71% and 29%, respectively. In Q3 FY25, the same stood at ~67% and ~33%, respectively.
โก1๐1๐1๐ซก1
#SALES #GROWTH 5 Year CAGR 17.8%
In FY24, sales increased by ~21% YoY to โน3,275 cr due to improvements across operational metrices. It witnessed growth in IP and OP volumes by 15% and 18%, respectively at a group level. Other metrics like occupancy rate, occupied bed days and ARPOB improved positively. Revenue from their mature and developing hospitals rose by ~18% and 34% YoY, respectively. Geographically, ~94% of the overall revenue constituted domestic patients, with remaining from the international patients. In 9M FY25, sales grew by ~12% YoY to โน2,761 cr, backed by higher inpatient volumes, supported by rising bed occupied days and strong contribution from the developing units. In Q3 FY25, in revenue terms, both matured (and developing hospitals grew by ~10% YoY, each. The key specialties contributed ~56% to revenue in Q3 FY25. In 9M FY25, a total of ~219 new beds were added to the existing capacity. From a YoY perspective, ~317 beds were added.
In FY24, sales increased by ~21% YoY to โน3,275 cr due to improvements across operational metrices. It witnessed growth in IP and OP volumes by 15% and 18%, respectively at a group level. Other metrics like occupancy rate, occupied bed days and ARPOB improved positively. Revenue from their mature and developing hospitals rose by ~18% and 34% YoY, respectively. Geographically, ~94% of the overall revenue constituted domestic patients, with remaining from the international patients. In 9M FY25, sales grew by ~12% YoY to โน2,761 cr, backed by higher inpatient volumes, supported by rising bed occupied days and strong contribution from the developing units. In Q3 FY25, in revenue terms, both matured (and developing hospitals grew by ~10% YoY, each. The key specialties contributed ~56% to revenue in Q3 FY25. In 9M FY25, a total of ~219 new beds were added to the existing capacity. From a YoY perspective, ~317 beds were added.
โก1๐1๐ฅ1๐1๐ซก1
#EBITDA #GROWTH 5 Year CAGR 41.6%
In FY24, EBITDA increased by ~27% YoY to โน799 cr. The increase was primarily attributable to case mix and bed expansions. During the period, it witnessed a rise in employee benefit expense due to the launch of Medanta labs and investments towards a new asset light model project in Indore. Purchase of pharmacy, lab and medical consumables constituted ~21% of the total revenue followed by manpower expense of ~35% (which constitutes employee benefit expense of 22% and consultant fees to doctors of 13%) . In 9M FY25, EBITDA increased by ~5% YoY to โน652 cr, led by bed expansions and case mix. In Q3 FY25, EBITDA for the mature hospitals was โน162 cr (up by ~9% YoY), while that of developing hospitals stood at โน102 cr (up by ~5% YoY).
In FY24, EBITDA increased by ~27% YoY to โน799 cr. The increase was primarily attributable to case mix and bed expansions. During the period, it witnessed a rise in employee benefit expense due to the launch of Medanta labs and investments towards a new asset light model project in Indore. Purchase of pharmacy, lab and medical consumables constituted ~21% of the total revenue followed by manpower expense of ~35% (which constitutes employee benefit expense of 22% and consultant fees to doctors of 13%) . In 9M FY25, EBITDA increased by ~5% YoY to โน652 cr, led by bed expansions and case mix. In Q3 FY25, EBITDA for the mature hospitals was โน162 cr (up by ~9% YoY), while that of developing hospitals stood at โน102 cr (up by ~5% YoY).
๐2โก1๐ฅ1๐1๐ซก1
#PAT #GROWTH 5 Year CAGR 51.0%
In FY24, PAT increased by ~47% YoY to โน478 cr. The growth was supported by increase in operating profit and lower finance costs. During the period, other income rose significantly due to rising interest income on bank deposits. In 9M FY25, PAT increased by ~8% YoY to โน380 cr. The growth was supported by lower finance costs, offset by higher other income during the period. Increase in the occupancy rate along with ARPOB at both mature and developing units would help in improving profitability. Further, the company is focusing on ramping up their new units.
In FY24, PAT increased by ~47% YoY to โน478 cr. The growth was supported by increase in operating profit and lower finance costs. During the period, other income rose significantly due to rising interest income on bank deposits. In 9M FY25, PAT increased by ~8% YoY to โน380 cr. The growth was supported by lower finance costs, offset by higher other income during the period. Increase in the occupancy rate along with ARPOB at both mature and developing units would help in improving profitability. Further, the company is focusing on ramping up their new units.
โก1๐ฅ1๐1